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INTRODUCTION
In developed countries, pancreatic cancer (PC) remains 
in the top 5 of most frequent causes of death due to cancer. 
Furthermore, the incidence of PC, although still low in most 
populations compared to other cancers, has been increasing 
steadily in the past years [1]. The most frequent type of PC 
is pancreatic ductal adenocarcinoma (PDAC), an aggressive 
form originating from the epithelium of the pancreatic duct. 
Despite improvements in PC research, the etiology of PDAC, 
reliable markers for early diagnosis and effective treatment 
options remain largely undetermined, resulting in a high 
mortality rate and short survival time after recognition of 
the disease. Considering that, up until now, only a few PDAC 
markers have been routinely used in clinical practice with lim-
ited sensitivity and specificity, extensive research is being con-
ducted to identify novel diagnostic, predictive and prognostic 
biomarkers for PDAC.
Neural precursor cell expressed developmentally 
down-regulated protein 9 (NEDD9), also known as EF1 and 
CAS-L, was originally identified based on its downregu-
lated expression pattern during the development of mouse 
brain [2,3]. NEDD9 is a member of Crk-associated substrate 
(CAS) family of adaptor molecules which also includes breast 
cancer anti-estrogen resistance protein 1 (BCAR1 or p130Cas), 
embryonal fyn-associated substrate (EFS or SIN), and Cas 
scaffolding protein family member 4 (CASS4 or HEPL). 
NEDD9 has been implicated in cancer and its overexpres-
sion was associated with tumor progression. For example, 
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ABSTRACT
Extensive research is being conducted to identify novel diagnostic, predictive and prognostic biomarkers for pancreatic ductal adenocarcinoma 
(PDAC), as only a few markers have been routinely used so far with limited success. Our aim was to assess the expression of neural precur-
sor cell expressed developmentally down-regulated protein 9 (NEDD9), E-cadherin, and γ-catenin in PDAC in relation to clinicopathological 
parameters and patient survival. We also investigated if there is a correlation of NEDD9 expression with E-cadherin or γ-catenin. The protein 
expression was determined by immunohistochemistry in 61 PDAC and 61 samples of normal pancreatic tissue. The log rank test and Kaplan-
Meier survival curve were used for survival analysis. E-cadherin and γ-catenin expressions were reduced in PDAC, and completely retained 
in normal pancreatic tissue. Expression of NEDD9 was significantly increased in PDAC (strong expression in 78.7% of cases and moderate in 
21.3%) and reduced in normal pancreatic tissue (strong positivity in 45.9% of cases, moderate in 31.1%, and weak in 23%). There was a positive 
correlation between reduced E-cadherin and γ-catenin expression in PDAC (p = 0.015). The loss or reduced expression of E-cadherin had a 
negative impact on patient survival (p = 0.020). A negative correlation between E-cadherin expression and tumor grade was also observed 
(p = 0.011). Decreased E-cadherin expression was more common in male patients with PDAC (81.3% vs. 60% for females, p = 0.005). γ-catenin 
and NEDD9 expressions were not statistically correlated with tumor stage and grade, gender, nor with patient survival. Our results support the 
role of NEDD9, E-cadherin and γ-catenin proteins in PDAC, but further research should clarify in detail their mechanism of action in pancre-
atic cancer.
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activation of NEDD9 was demonstrated in melanoma where 
it could enhance cancer cell invasion in vitro and metastasis 
in a mouse model in vivo [4]. Moreover, NEDD9 overexpres-
sion directed elongation and mesenchymal-type invasion in 
melanoma cells by engaging integrin avb3 and recruiting Src 
kinase [5]. A recent study [2] also showed increased mRNA 
and protein levels of NEDD9 in pancreatic carcinoma lesions 
compared to the paired adjacent non-tumor tissue. In the 
same study, a high NEDD9 expression was statistically cor-
related with clinical staging, lymph node metastasis, and his-
tological differentiation [2].
E-cadherin or cadherin-1 is a type of calcium-dependent 
transmembrane glycoprotein with a function in mediating cell-
cell adhesion between epithelial cells. Structurally, E-cadherins 
are composed of three domains: an extracellular domain, 
which extends from the surface of the cell and binds to cad-
herins on adjacent cells, transmembrane domain composed of 
glycoprotein repeats, and intracellular or cytoplasmic domain 
which binds various cytoplasmic proteins, including catenins. 
There are four types of catenins: α, β, δ and γ. E-cadherin spe-
cifically binds to β- or γ-catenin, while α-catenin binds either 
to β-catenin or γ-catenin, but not to E-cadherin. δ- or p120-cat-
enin binds to a juxtamembrane domain of E-cadherin. β-cat-
enin possesses an armadillo domain which consists of char-
acteristic repeats folded together into an elongated shape and 
functions as a ligand-binding site. β-catenin is also the main 
component of the Wnt signaling pathway and can act as an 
oncogene [6]. α-catenin links the cadherin-catenin complex 
to actin filaments via vinculin and alpha actins. α-catenin can 
also regulate the arrangement of actin filaments  [7,8]. γ-cat-
enin or plakoglobin is a component of desmosomes but may 
also bind to classical cadherins. It has been implicated in the 
control of epithelial cell motility, i.e.  low levels of γ-catenin 
correlated with higher cell motility [9,10]. Overall, these cell-
cell contacts maintain the structural integrity of tissues [7,8], 
and lower E-cadherin expression or complete loss have been 
linked to several tumor types.
The aim of this study was to evaluate immunohistochemi-
cal expression of NEDD9, E-cadherin and γ-catenin in PDAC 
patients in relation to clinicopathological parameters and 
patient survival. We also investigated if there is a correlation 
of NEDD9 expression with E-cadherin or γ-catenin in PDAC, 
as E-cadherin was demonstrated to be a downstream target 
of NEDD9.
MATERIALS AND METHODS
Samples and patients
We obtained 61 tumor and 61 normal pancreatic tissue 
samples from patients with PDAC who underwent pancre-
atectomy at our institution between 2000 and 2012. All slides 
were re-evaluated for the purpose of this study. There were 
30 male and 31 female patients, with the age range 32–78 years.
Immunohistochemistry
The expression of NEDD9, E-cadherin and γ-catenin 
was determined in 61 samples of PDAC and 61 normal pan-
creatic tissues by measuring the intensity of immunohisto-
chemical staining and percentage of positive tumor cells. 
Immunohistochemical analyses were performed using forma-
lin-fixed, paraffin-embedded (FFPE) tissue sections (thickness 
5 μm). Deparaffinization and immunohistochemical staining 
were carried out using a microwave streptavidin immunop-
eroxidase (MSIP) protocol and labeled streptavidin-biotin 
(LSAB) method on a DAKO TechMateTM Horizon automated 
immunostainer (DAKO, Denmark). Monoclonal antibodies 
were directed against NEDD9 (sab 4200376, dilution 1:200, R 
Sigma, USA), E-cadherin (Clone NCH-38, dilution 1:50, Dako, 
Denmark) and γ-catenin (ab 15153, dilution 1:100, R Sigma, 
USA).
Immunoreaction was detected in epithelial tumor cells as 
well as in the epithelial component of metastatic lymph nodes 
in the areas with the highest activity ("hot spots") under mag-
nification of ×400, for a total of 1,000 tumor cells. The "hot 
spot" was determined upon inspection of the whole section 
(magnification of ×40).
The immunohistochemical staining for NEDD9 and 
γ-catenin was scored as follows: 0 - no reaction or weak cyto-
plasmic staining in <25% of tumor cells; 1 - weak cytoplasmic 
staining in >25% of tumor cells; 2 - moderate staining in >25% of 
tumor cells; and 3 - strong staining in >25% of tumor cells [4].
E-cadherin staining was considered absent when the stain-
ing was either absent or present only in <5% of cancer cells. The 
staining was considered positive if the intensity was strong 
(2+) or weak (1+) and if it was detected in ≥5% of tumor cells. 
As previously described, we classified E-cadherin expression 
as “intact” when 100% of tumor cells in the tissue were stained, 
“focal loss” when ≥51% and <99% of tumor cells were labeled, 
“diffuse loss” when ≥6% and ≤50% of tumor cells were labeled 
and “total loss” when <5% of tumor cells were labeled. We did 
not evaluate other cut-offs of expression percentages [11].
Follow-up data
Additional information was collected as follows: patient 
age, gender, tumor size, tumor grade, number of resected 
lymph nodes, number of positive lymph nodes, follow-up 
duration, and survival time.
Statistical analysis
Nominal categorical data were presented as frequencies 
and proportions, while numerical data were shown as medians. 
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The normality of distribution was tested by the Kolmogorov–
Smirnov test. NEDD-9, γ-catenin and E-cadherin expression 
values were compared between tumor and control samples by 
chi-squared test. A  relationship between clinicopathological 
parameters and immunohistochemical markers was analyzed 
by Spearman’s rank correlation coefficient. The log rank test 
and Kaplan-Meier survival curve were used to analyze sur-
vival in relation to immunohistochemical markers. A value of 
p < 0.05 was considered statistically significant. Statistical anal-
yses were performed using IBM SPSS Statistics for Windows, 
Version 21.0. (IBM Corp., Armonk, NY).
RESULTS
Clinicopathological characteristics of patients with 
PDAC
The study included 30 male and 31 female patients with the 
age ranging from 32 to 78 years (median 62). Tumor size ranged 
from 1.5 to 10 cm (median 3.5), and the majority of tumors (59%) 
were grade 2. Lymph nodes were negative for tumor cells in 26 
and positive in 29 cases. In 6 cases, lymph nodes were not sam-
pled. In 3 cases, metastases were present at the time of opera-
tion. The number of positive lymph nodes in each patient varied 
from 0 to 6 with the mean proportion of positive lymph nodes 
being 20.95%. The follow-up ranged 1–139  months (median 
12.4). In that period, 52 patients died of the disease, 7 were still 
alive, and for 2 patients there was no data about survival.
Immunohistochemical expression of NEDD9, 
γ-catenin, and E-cadherin
In PDAC group, the expression of NEDD9 was strong in 
78.7% cases, moderate in 21.3%, and there was no case with 
weak expression of NEDD9. In control group, normal pancre-
atic tissue was strongly positive for NEDD9 in 45.9% of cases, 
moderately positive in 31.1%, and weakly positive in 23% of 
cases. The difference in NEDD9 expression was significantly 
different between the two groups.
E-cadherin expression was analyzed as the intensity of 
cytoplasmic staining as well as preserved and focally or dif-
fusely lost expression. We found that E-cadherin expression 
was completely intact and strongly positive in all cases of 
normal pancreatic tissue, while in PDAC tissue E-cadherin 
expression was mostly weak (73.8% of cases) and focally lost 
(45.9 % of cases). In PDAC group, low E-cadherin expres-
sion was more common in male (60%, p < 0.005) and higher 
E-cadherin expression in female patients (81.3%). Moreover, 
weak staining of E-cadherin was more often found in moder-
ate- (62.2%) and high-grade PDAC (26.7%), strong E-cadherin 
staining was more common in moderate-  (50%) and low-
grade  PDAC [43.8%] (Table  1, Figure  1). E-cadherin expres-
sion was statistically more often (p < 0.001) diffusely (24.4%) 
or focally (57.8%) lost in PDAC samples with weak staining, 
while in specimens with strong E-cadherin staining the 
expression was preserved in the majority of cases (81.3%). In 
normal pancreatic tissue, γ-catenin expression was high in 
FIGURE 1. (A) High expression of neural precursor cell expressed developmentally down-regulated protein 9 (NEDD9) in pancreatic 
ductal adenocarcinoma [PDAC] (200×). (B) High expression of E-cadherin in normal pancreatic tissue [left] and low expression in PDAC 
[right] (100×). (C) High expression of E-cadherin in PDAC (100×). (D) High γ-catenin expression in PDAC (100×).
A
C
B
D
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98.4% and moderate in 16% of cases. In PDAC tissue, γ-catenin 
expression was high in 72.1%, moderate in 26.2%, and low in 
1.6% of specimens (Figure 1).
Survival analysis
We observed a positive correlation between reduced 
E-cadherin and γ-catenin expression in PDAC group, as well 
as a positive correlation between E-cadherin expression and 
patient survival (log rank test, p = 0.020); i.e.  patients with 
higher E-cadherin expression had longer survival after pan-
createctomy (Figure 2). γ-catenin expression was not statisti-
cally correlated with the tumor stage, tumor grade, gender, nor 
with patient survival. Also, there was no correlation between 
NEED9 and survival time, despite higher NEED9 expression 
in tumor samples.
DISCUSSION
To be able to spread beyond the primary tumor site 
cancer cells must undergo changes in molecular mecha-
nisms that control cell proliferation, growth, ability to avoid 
immune response, and cell-cell interaction. Changes in the 
expression of NEDD9 have been associated with hyper-
proliferation and invasion in some tumors. As a scaffold 
protein, NEDD9 assembles signaling complexes with other 
molecules, which then regulate multiple cellular processes, 
most of them being important for cancer development and 
progression. Furthermore, by regulating downstream tar-
gets, including E-cadherin (and possibly γ-catenin), NEDD9 
is able to affect various cellular functions and processes such 
as migration, invasion, survival and multiplication. Although 
NEDD9 most probably does not have a direct oncogenic 
effect, a higher expression of NEDD9 is commonly observed 
in tumor cells and affects tumor aggressiveness and response 
to treatment [12].
A number of studies showed that NEDD9 overexpres-
sion is associated with metastasis in different cancer types, 
including breast cancer, glioblastoma, melanoma and cervi-
cal cancer [4,13-15]. Štajduhar et  al. found increased expres-
sion of NEDD9 in epithelial and stromal components of 
axillary lymph node metastases of breast cancer compared 
to non-metastatic tumors [13]. Another study showed that 
NEDD9 could enhance metastasis in an inducible mouse 
model of melanoma [4]. Moreover, NEDD9 together with 
BCAR1 promoted the removal of E-cadherin from the cell 
membrane and lysosomal degradation through Src kinase in 
MCF7 breast adenocarcinoma cells, thus probably contribut-
ing to the epithelial-mesenchymal transition (EMT) of tumor 
cells [16]. Nevertheless, in our study, there was no correlation 
between NEDD9 and E-cadherin expression in PDAC cells. 
TABLE 1. Immunohistochemical expression of E-cadherin, neural precursor cell expressed developmentally down-regulated protein 9 
(NEDD-9), and γ-catenin in relation to clinicopathological data of patients with pancreatic ductal adenocarcinoma (PDAC)
Immunohistochemical 
expression in tumor
E-cadherin NEDD9 γ-catenin
Low (1) High (2) Low (1) Medium (2) High (3) Low (1) Medium (2) High (3)
N % N % N % N % N % N % N % N %
Gender Male 27 60 3 18.8 0 0 6 46.2 24 50 1 100 10 62.5 19 43.2
Female 18 40 13 81.3 0 0 7 53.8 24 50 0 0 6 37.5 25 56.8
Tumor 1 4 8.9 2 12.5 0 0 1 7.7 5 10.4 0 0 2 12.5 4 9.1
2 8 17.8 3 18.8 0 0 4 30.8 7 14.6 0 0 3 18.8 8 18.2
3 32 71.1 11 68.8 0 0 8 61.5 35 72.9 1 100 11 68.8 31 70.5
4 1 2.2 0 0 0 0 0 0 1 2.1 0 0 0 0 1 2.3
Node 0 18 45 7 46.7 0 0 4 36.4 21 47.7 1 100 5 35.7 19 47.5
1 22 55 8 53.3 0 0 7 63.6 23 52.3 0 0 9 64.3 21 52.5
Metastasis 1 3 100 0 0 0 0 0 0 3 100 0 0 2 100 1 100
Grade 1 5 11.1 7 43.8 0 0 1 7.7 11 22.9 0 0 2 12.5 10 22.7
2 28 62.2 8 50 0 0 9 69.2 27 56.3 1 100 11 68.8 24 54.5
3 12 26.7 1 6.3 0 0 3 23.1 10 20.8 0 0 3 18.8 10
FIGURE 2. The Kaplan-Meier analysis of cumulative survival in 
relation to E-cadherin expression in pancreatic ductal adenocarci-
noma [PDAC]. A positive correlation between E-cadherin expres-
sion and patient survival was observed (log rank test; p = 0.020); 
i.e. patients with higher E-cadherin expression had longer survival 
after pancreatectomy.
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Other studies showed that higher expression of NEDD9 was 
characteristic for aggressive tumors positive for Ras activation, 
p16 inhibition, BCR-ABL translocation, or transformation of 
human T-cell lymphotropic virus type  1 (HTLV-1)-infected 
cells [4,17]. These initial molecular changes, associated with 
increased NEDD9 expression, lead to the inhibition of apop-
tosis or inactivation of the mitotic checkpoint, and thus pro-
mote the invasive potential of tumor cells. In their review, 
Mahendra et  al. indicated the important role of NEDD9 in 
the regulation of cell cycle, apoptosis, cell attachment, migra-
tion, and invasion [18]. Xue et  al. [2] showed higher mRNA 
and protein NEDD9 levels in 106 PDAC compared to adjacent 
normal tissue. Higher expression of NEDD9 was correlated 
with higher tumor stage, lower differentiation and with lymph 
node metastases. Moreover, they reported a negative correla-
tion between patient survival and NEDD9 expression and 
indicated that NEDD9 might serve as an independent factor 
of poor prognosis [2]. Our study also showed significantly 
higher expression of NEDD9 in PDAC (Figure 1) compared to 
normal pancreatic tissue, however, we did not observe a cor-
relation between NEDD9 and tumor grade, stage or patient 
survival.
E-cadherin expression was lower in our PDAC group 
compared to normal pancreatic tissue (Figure  1). Different 
mechanisms may lead to E-cadherin inactivation in malignant 
cells, including mutations, DNA methylation, gene silencing 
and endocytosis. Endocytosis and degradation of E-cadherin 
can be the result of the activation of proto-oncogenes such as 
Src and epidermal growth factor receptor (EGFR), as shown in 
a study by Nagathihalli and Mershant [19] where higher activ-
ity of Src tyrosine kinase was common in PDAC, regulating 
E-cadherin function and EMT and leading to increased tumor 
progression, invasion and metastasis [19]. In our study, lower 
E-cadherin expression was more common in higher-grade 
tumors, confirming the role of E-cadherin in tumor progres-
sion. Pećina-Šlaus et al. found lower E-cadherin expression in 
higher-grade meningeomas [20]. Hong et al. [11] also demon-
strated that lower expression of E-cadherin was more com-
mon in high-grade PDAC, while Pryczynicz et al. [21] did not 
find a correlation between E-cadherin expression and tumor 
grade or lymph node metastases. An in vitro study using JHP-1 
adenocarcinoma cell line showed that the downregulation of 
E-cadherin in pancreatic carcinoma cells promoted the inva-
siveness into the basement membrane, and similarly in vivo 
selection of highly metastatic murine pancreatic cancer cells 
induced EMT by genetic inactivation of E-cadherin in paren-
tal cells [22,23].
Focally lost E-cadherin expression was more common in 
our sample and it was also correlated with intermediate γ-cat-
enin expression. Lupu-Meiri et  al. suggested plasminogen 
activator inhibitor-1 (PAI-1) as another factor that suppresses 
differentiation of PDAC cells by inhibiting E-cadherin expres-
sion [24].
Other studies confirmed that total or partial loss of 
E-cadherin expression is correlated with shorter survival of 
patients [11,25]. In the present study, patient survival was pos-
itively correlated with preserved and high E-cadherin expres-
sion, which may be explained by higher cell adhesions in 
those PDACs that were less likely to migrate and metastasize. 
Therefore, our study confirms that diminished expression of 
E-cadherin strongly affects EMT and metastatic potential of 
tumor cells.
We observed lower E-cadherin expression more fre-
quently in male patients and higher in female patients, but 
there was no significant difference in survival between men 
and women. Contrary to our study, Pryczynicz et al. did not 
find a correlation between E-cadherin expression and patient 
gender [21].
We detected lower γ-catenin expression in PDAC com-
pared to normal pancreatic tissue, where its expression was 
high. γ-catenin has an important role in maintaining epi-
thelial integrity and despite having the same binding site to 
E-cadherin as β-catenin, it has a different oncogenic activ-
ity. Generally, a tumor-suppressor role has been suggested 
for γ-catenin [21,26]. Charpentier et  al. [27] found that even 
modest expression of two γ-catenin transgenes was able to 
decrease the proliferation in basal epidermal cells in mouse 
and to significantly reduce the length of the growth phase in 
the hair follicle cells [27]. Also, studies showed that, in a cell 
culture, keratinocytes lacking γ-catenin were less adherent 
and exhibited a higher cell migration [3]. In addition, lower 
γ  -catenin expression was correlated with the invasiveness 
of breast cancer [28]. Nevertheless, our results indicated no 
correlation between γ-catenin expression and patient survival.
CONCLUSION
In summary, reduced and focally or diffusely lost expres-
sion of E-cadherin and reduced expression of γ-catenin was 
observed in PDAC, while high and completely preserved 
E-cadherin expression and high γ-catenin expression was 
detected in normal pancreatic tissue. Our study indicated 
a strong correlation of reduced E-cadherin expression with 
reduced γ-catenin expression, tumor grade, and patient sur-
vival. On the other hand, expression of NEDD9 was increased 
in PDAC and reduced in normal pancreatic tissue. Overall, 
our results support the role of NEDD9 and cadherin/catenin 
proteins as biomarkers in PDAC, as well as their use in devel-
oping more effective therapies for this aggressive form of can-
cer. Nevertheless, additional studies are necessary to clarify in 
detail the mechanism of action and interaction of these pro-
teins in PDAC.
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